Leadership & Pay ·
Avalyn Pharma Inc. appointed Robert Meyer, M.D., as a Class II director effective September 15, 2026, with his term…
AVLNAvalyn Pharma Inc.
Avalyn Pharma Inc. appointed Robert Meyer, M.D., as a Class II director effective September 15, 2026, with his term expiring at the 2028 annual meeting. Dr. Meyer brings extensive regulatory and clinical experience from roles at Merck & Co., the FDA, Greenleaf Health Inc., and other life sciences companies. He received an initial stock option grant for 31,182 shares vesting over three years, plus a pro-rated annual grant of 15,591 options upon his first annual meeting, alongside a $40,000 annual retainer. Avalyn Pharma Inc. operates in the biopharmaceutical industry.